Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress

Lyell Immunopharma announced updated safety data for ronde-cel, its dual-targeting CD19/CD20 CAR T-cell therapy, showing no Grade ≥3 cytokine release syndrome and low Grade ≥3 neurotoxicity rates in over 100 patients with relapsed/refractory large B-cell lymphoma. Translational data revealed enhanced memory potential of CAR T cells and durable responses, particularly in patients with low antigen expression. The company expects pivotal trial data in mid-2027 with BLA submission to follow.

06/12/2026, 12:45 PM • GlobeNewswire

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

Lyell Immunopharma announced positive safety data for LYL273, its GCC-targeted CAR T-cell therapy for metastatic colorectal cancer. Gastrointestinal prophylaxis significantly reduced Grade ≥2 diarrhea/colitis from 55% to 10%, with no Grade ≥3 cytokine release syndrome or neurotoxicity observed. The Phase 1 trial has been amended to Phase 1/2 design to enable seamless expansion into a potential pivotal Phase 2 trial, with an End-of-Phase 1 FDA meeting expected by end of 2026.

06/08/2026, 6:00 AM • GlobeNewswire

Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer

Lyell Immunopharma closed an additional $50 million tranche from its $100 million equity private placement following achievement of a clinical milestone for rondecabtagene autoleucel (ronde-cel) in its PiNACLE pivotal trial for relapsed/refractory large B-cell lymphoma. The company also appointed Smital Shah as Chief Financial and Business Officer. With this funding, Lyell expects sufficient cash runway into Q2 2027.

03/09/2026, 8:00 AM • GlobeNewswire

Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors

Century Therapeutics announced the appointments of Dr. Han Lee and Dr. Martin Murphy to its Board of Directors, bringing extensive experience in biotechnology, corporate development, and life science investment.

12/09/2025, 8:00 AM • GlobeNewswire

Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition

Lyell Immunopharma reported promising clinical trial results for ronde-cel, a CAR T-cell therapy targeting large B-cell lymphoma, showing high response rates and a manageable safety profile across multiple treatment lines.

12/07/2025, 4:30 PM • GlobeNewswire

Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition

Lyell Immunopharma presented clinical trial data for ronde-cel, a dual-targeting CD19/CD20 CAR T-cell therapy for aggressive large B-cell lymphoma, highlighting promising response rates and safety profile at the 67th ASH Annual Meeting.

11/03/2025, 9:00 AM • GlobeNewswire

Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments

Several biotech companies are developing innovative cancer treatments, with promising clinical trial results in various cancer types, focusing on immunotherapy and personalized medicine approaches.

07/29/2025, 3:46 PM • Benzinga

Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series

Lyell Immunopharma announced positive clinical data for its lead product candidate LYL314, an autologous dual-targeting CD19/CD20 CAR T-cell therapy, in the treatment of relapsed and/or refractory large B-cell lymphoma. The data showed high rates of durable complete responses in patients treated in the third- or later-line setting.

06/23/2025, 5:00 PM • GlobeNewswire